Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D trimmed its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 2.0% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 84,121 shares of the company’s stock after selling 1,705 shares during the period. State of New Jersey Common Pension Fund D owned 0.08% of Intellia Therapeutics worth $1,729,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NTLA. First Horizon Advisors Inc. lifted its stake in Intellia Therapeutics by 22.1% during the second quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock worth $58,000 after purchasing an additional 472 shares during the last quarter. Elmwood Wealth Management Inc. boosted its holdings in shares of Intellia Therapeutics by 0.9% in the 3rd quarter. Elmwood Wealth Management Inc. now owns 67,774 shares of the company’s stock valued at $1,393,000 after buying an additional 600 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Intellia Therapeutics by 27.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after buying an additional 794 shares during the last quarter. Axxcess Wealth Management LLC raised its stake in Intellia Therapeutics by 6.5% during the first quarter. Axxcess Wealth Management LLC now owns 16,602 shares of the company’s stock worth $457,000 after acquiring an additional 1,010 shares during the period. Finally, Intellectus Partners LLC lifted its holdings in Intellia Therapeutics by 2.1% in the second quarter. Intellectus Partners LLC now owns 58,225 shares of the company’s stock worth $1,303,000 after acquiring an additional 1,225 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Price Performance

NASDAQ NTLA opened at $14.17 on Tuesday. The company has a market capitalization of $1.44 billion, a P/E ratio of -2.58 and a beta of 1.81. Intellia Therapeutics, Inc. has a 12 month low of $13.54 and a 12 month high of $34.87. The company’s 50 day simple moving average is $18.64 and its 200 day simple moving average is $22.04.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics’s quarterly revenue was down 24.1% on a year-over-year basis. During the same period in the prior year, the company posted ($1.38) EPS. On average, analysts anticipate that Intellia Therapeutics, Inc. will post -5.13 earnings per share for the current year.

Insider Activity

In related news, CAO Michael P. Dube sold 2,012 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total value of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at approximately $893,698.12. This represents a 4.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.20% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on NTLA. Wedbush reiterated a “neutral” rating and set a $14.00 price target on shares of Intellia Therapeutics in a research report on Monday. The Goldman Sachs Group cut their target price on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Royal Bank of Canada restated an “outperform” rating and set a $54.00 price target on shares of Intellia Therapeutics in a research report on Thursday, September 19th. Stifel Nicolaus cut their price objective on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating on the stock in a research report on Wednesday, September 11th. Finally, Oppenheimer decreased their target price on shares of Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $53.88.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.